Letter to the editor: Anti-RAS drugs and SARS-CoV-2 infection

Letter to the editor: Anti-RAS drugs and SARS-CoV-2 infection

Bibliographic Details
Main Authors:	Jingwei Bian, Rongsheng Zhao, Suodi Zhai, Zijian Li
Format:	Article
Language:	English
Published:	Elsevier 2020-07-01
Series:	Acta Pharmaceutica Sinica B
Online Access:	http://www.sciencedirect.com/science/article/pii/S2211383520305566

Similar Items

Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator
by: Jingwei Bian, et al.
Published: (2021-01-01)

Reply to Letter to Editor: Is SARS-CoV-2 responsible for relapses of Parkinson’s disease?
by: Walaa A. Kamel, et al.
Published: (2021-09-01)

Response to letter to the editor “Does SARS-CoV-2 truly cause infectious myopathy?”
by: Kai Chieh Chang
Published: (2021-03-01)

Designing Inhibitors for the SARS CoV Main Protease as Anti-SARS Drugs
by: Hamza Bari, et al.
Published: (2020-12-01)

Discrepancy in Screening Performances of Different Rapid Test Kits for SARS-CoV-2; a Letter to Editor
by: Phee Kheng Cheah, et al.
Published: (2020-12-01)

Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19)
by: Surjeet Verma, et al.
Published: (2020-09-01)

SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
by: Hatem A. Elshabrawy
Published: (2020-06-01)

Diabetes and coronavirus infections (SARS-CoV, MERS-CoV, and SARS-CoV-2)
by: Azadeh Haghi Navand, et al.
Published: (2020-01-01)

Data mining of coronavirus: SARS-CoV-2, SARS-CoV and MERS-CoV
by: Jung Eun Huh, et al.
Published: (2021-04-01)

Comparison between SARS-CoV and SARS-CoV 2
by: Fang Meng
Published: (2021-01-01)

Letter to the Editor: Microbiota in the Respiratory System—A Possible Explanation to Age and Sex Variability in Susceptibility to SARS-CoV-2
by: Vishal Shah
Published: (2021-01-01)

Anti-SARS-CoV and Anti-cancer Effects of Emodin
by: Mohammad Hossein Ghaffari Agdam, et al.
Published: (2019-08-01)

SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
by: T.M. Abdelghany, et al.
Published: (2021-03-01)

SARS-CoV-2 and Anti-Cardiolipin Antibodies
by: Mazen Jizzini, et al.
Published: (2020-12-01)

The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates
by: Gang Ye, et al.
Published: (2021-08-01)

Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs
by: Ujjwal Neogi, et al.
Published: (2020-04-01)

Anti–SARS‐CoV‐2 Repurposing Drug Database: Clinical Pharmacology Considerations
by: Xinyuan Zhang, et al.
Published: (2021-09-01)

Immunomodulatory Drugs in the Management of SARS-CoV-2
by: Daniel R. Burrage, et al.
Published: (2020-08-01)

Letter to the Editor Regarding Torres-Costa et al “SARS-CoV-2 in Ophtalmology: Current Evidence and Recommendations for Clinical Practice”
by: Thiago Gonçalves dos Santos Martins
Published: (2021-01-01)

Letter to the Editor: Can the seasonal influenza vaccine for 2019/2020 have cross reactivity with some of the SARS-CoV-2 proteins?
by: Milad Zandi, et al.
Published: (2021-09-01)

The emerging SARS-CoV, MERS-CoV, and SARS-CoV-2: An insight into the viruses zoonotic aspects
by: Karima A. Al-Salihi, et al.
Published: (2021-01-01)

Computational analysis of SARS-CoV-2, SARS-CoV, and MERS-CoV genome using MEGA
by: Vipan Kumar Sohpal
Published: (2020-09-01)

The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections
by: Yun-yu Zhang, et al.
Published: (2020-08-01)

Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery
by: Zhonglei Wang, et al.
Published: (2021-01-01)

Coronavirus in Continuous Flux: From SARS‐CoV to SARS‐CoV‐2
by: Yetian Dong, et al.
Published: (2020-10-01)

Differential Tropism of SARS-CoV and SARS-CoV-2 in Bat Cells
by: Susanna K.P. Lau, et al.
Published: (2020-12-01)

Electrostatic features for nucleocapsid proteins of SARS-CoV and SARS-CoV-2
by: Wenhan Guo, et al.
Published: (2021-04-01)

Structure and Function of Major SARS-CoV-2 and SARS-CoV Proteins
by: Ritesh Gorkhali, et al.
Published: (2021-06-01)

Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses
by: Zeinab Abdelrahman, et al.
Published: (2020-09-01)

Autopsy Tool in Unknown Diseases: The Experience with Coronaviruses (SARS-CoV, MERS-CoV, SARS-CoV-2)
by: Francesco Sessa, et al.
Published: (2021-03-01)

Anti-rheumatic in SARS-CoV-2: benefit or risk?
by: Francesco Ferrara
Published: (2020-04-01)

Challenges and Issues of Anti-SARS-CoV-2 Vaccines
by: Sophie Blumental, et al.
Published: (2021-05-01)

Potential Anti-SARS-CoV-2 Molecular Strategies
Published: (2023)

SARS-CoV-2: Virology and Drug Repurposing Approaches
by: Ratika Rahmasari, et al.
Published: (2020-07-01)

Drug Weaponry to Fight Against SARS-CoV-2
by: Elena Cabezón, et al.
Published: (2020-08-01)

Phytochemicals against SARS-CoV as potential drug leads
by: Shasank Sekhar Swain, et al.
Published: (2021-03-01)

Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
by: Jiri Patocka, et al.
Published: (2021-03-01)

Computational designing of a peptide that potentially blocks the entry of SARS-CoV, SARS-CoV-2 and MERS-CoV.
by: Priya V K, et al.
Published: (2021-01-01)

Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19
by: Kening Li, et al.
Published: (2020-11-01)

NeoCoV Is Closer to MERS-CoV than SARS-CoV
by: Mohamed M Hassan, et al.
Published: (2020-06-01)